We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

NICE Sample Clauses

NICE. (v) Healthwatch England and Local Healthwatch; (vi) the General Medical Council; (vii) the General Dental Council; (viii) the General Optical Council; (ix) the General Pharmaceutical Council; (x) the Healthcare Safety Investigation Branch; and (xi) the Information Commissioner; Relevant Information means the Personal Data and Non-Personal Data processed under the Delegation and this Agreement, and includes, where appropriate, “confidential patient information” (as defined under section 251 of the NHS Act), and “patient confidential information” as defined in the 2013 Report, The Information Governance Review – “To Share or Not to Share?”);
AutoNDA by SimpleDocs
NICE. Locally defined objectives include: • Delivery of efficiencies to address the Health and Social Care financial challenge.
NICE. (v) Healthwatch England and Local Healthwatch; (vi) the General Medical Council; (vii) the General Dental Council; (viii) the General Optical Council; (ix) the General Pharmaceutical Council; (x) the Healthcare Safety Investigation Branch; and (xi) the Information Commissioner;
NICE. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]Published date: 14 March 2018 Last updated: 13 September 2019. Available at: xxxxx://xxx.xxxx.xxx.xx/guidance/ng87 [Accessed June 2020] NICE. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release. Evidence summary [ESNM70] 22 March 2016. Available at: xxxxx://xxx.xxxx.xxx.xx/advice/esnm70/chapter/Key-points-from-the-evidence [Accessed May 2020]
NICEMaintenance and monitoring for people taking medication for ADHD. Last Updated September 2019. Available at: xxxxx://xxxxxxxx.xxxx.xxx.xx/pathways/attention-deficit-hyperactivity-disorder#path=view%3A/pathways/attention-deficit-hyperactivity-disorder/maintenance-and-monitoring-for-people-taking-medication-for-adhd.xml&content=view-info-category%3Aview-resources-menu [Accessed June 2020] Joint Formulary Committee. British National Formulary for Children (BNFc). May 2020 Available at: xxxxx://xxxx.xxxx.xxx.xx/ [Accessed May 2020] Electronic Medicines Compendium. Summaries of Product Characteristics. Available at: xxxxx://xxx.xxxxxxxxx.xxx.xx/emc [Accessed June 2020] General Medical Council. Prescribing Unlicensed Medicines. Available at: xxxxx://xxx.xxx-xx.xxx/ethical-guidance/ethical-guidance-for-doctors/prescribing-and-managing-medicines-and-devices/prescribing-unlicensed-medicines [Accessed 17.6.20] NHS England. Responsibility for prescribing between Primary & Secondary/Tertiary Care. Publications Gateway Reference 07573. January 2018. Available at: xxxxx://xxx.xxxxxxx.xxx.xx/wp-content/uploads/2018/03/responsibility-prescribing-between-primary-secondary-care-v2.pdf [Accessed June 2020]
NICE. (2006). Dementia: Supporting people with Dementia and Their Carers in Health and Social Care. London: National Institute of Health and Care Excellence.
NICE. (e) Healthwatch England and Local Healthwatch; (f) Public Health England; (g) the General Pharmaceutical Council; (h) the Healthcare Safety Investigation Branch; (i) Information Commissioner; (j) European Data Protection Board; Special Categories of Personal Data As defined in Article 9 of the UK GDPR - Personal Data revealing: (a) racial or ethnic origin (b) political opinions (c) religious or philosophical beliefs (d) trade union membership (e) genetic data or biometric data identifying a natural person (f) data concerning health (g) data concerning a natural person's sex life or sexual orientation
AutoNDA by SimpleDocs
NICE. 4.1.1 The Provider will have systems in place, as relevant and applicable, that ensure the Service is delivered in accordance with current and emerging practice
NICE. 4.1.1 The Provider will have systems in place, as relevant and applicable, that ensure the Service is delivered in accordance with current and emerging practice guidance issued by the Department of Health, Public Health England, The Home Office, the National Institute for Health and Clinical Excellence and by Professional bodies or organisations specialising in the field of substance misuse treatment including, but not restricted to: The Royal College of Physicians; British Psychological Society; SCAN - Specialist Clinical Addiction Network; Substance Misuse Management in General Practice; Royal College of General Practitioners; Association of Nurses in Substance Abuse; the Royal Pharmaceutical Society; Institute of Psychiatry; the Royal College of Nursing; the British Association of Social Workers; Care Quality Commission; Monitor, and the Federation of Drug and Alcohol Professionals.
NICE. COVID-19 rapid guideline: managing the long-term effects of COVID- 19. NG188. 2020. Accessed 29.04.21: xxxxx://xxx.xxxx.xxx.xx/guidance/NG188 6. ONS (2020) The prevalence of long COVID symptoms and COVID-19 complications. Accessed 29.04.21: xxxxx://xxx.xxx.xxx.xx/news/statementsandletters/theprevalenceoflongcovid symptomsandcovid19complications 7. Xxxxx CH, Xxxxxx B, Xxxxxxxxx T, Xxxxxx MS, Xxxxxxx XX, Xxxxxx XX, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv [Internet]. 2020.10.19.20214494. Accessed 29.04.21: xxxx://xxxxxxx.xxx/content/early/2020/10/21/2020.10.19.20214494.abstract 8. Tenforde M, Xxx X, Xxxxxxxx C, al. e (2020) Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID- 19 in a Multistate Health Care Systems Network — United States, MMWR Morb Mortal Wkly Rep. 2020;ePub: Accessed 29.04.21 xxxx://xx.xxx.xxx/10.15585/mmwr.mm6930e1external
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!